Recursion (RXRX) CEO reports tax RSU withholding and 40K share sale
Rhea-AI Filing Summary
Recursion Pharmaceuticals (RXRX) CEO/Director Form 4 shows routine equity activity. On 11/17/2025, 40,390 Class A shares were withheld at $4.14 to cover tax obligations from net-settled restricted stock units, leaving 913,839 Class A shares directly owned. On 11/19/2025, the insider converted 40,000 Class B shares into Class A at $0 and sold 40,000 Class A shares at $4.16 under a Rule 10b5-1 trading plan adopted on May 12, 2025, maintaining direct ownership at 913,839 Class A shares.
The insider also reports derivative holdings, including Class B shares convertible into Class A with no expiration date and multiple stock options with exercise prices ranging from $2.48 to $11.40 and expirations extending to 2035. Some Class B holdings are reported indirectly through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 40,000 | $0.00 | $0.00 |
| Conversion | Class A Common Stock | 40,000 | $0.00 | $0.00 |
| Sale | Class A Common Stock | 40,000 | $4.16 | $166K |
| Exercise Price or Tax Liability | Class A Common Stock | 40,390 | $4.14 | $167K |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (11)
- F1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
- F2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
- F3. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
- F4. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
- F5. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
- F6. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
- F7. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F9. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F10. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F11. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did the RXRX CEO report on this Form 4?
The CEO of Recursion Pharmaceuticals (RXRX) reported three main transactions: 40,390 Class A shares withheld on 11/17/2025 to cover taxes on restricted stock units, the conversion of 40,000 Class B shares into Class A on 11/19/2025 at $0, and the sale of 40,000 Class A shares on 11/19/2025 at $4.16.
Was the RXRX CEO stock sale made under a Rule 10b5-1 trading plan?
Yes. The conversion and sale of 40,000 Class A shares on 11/19/2025 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025.
What is the relationship between RXRX Class B and Class A Common Stock for this insider?
Each reported share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
What indirect RXRX holdings does the CEO report?
The CEO reports indirect holdings of Class B Common Stock convertible into Class A through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust, where the CEO is a member, manager, or trustee.
What stock options in RXRX does the CEO hold according to this Form 4?
The CEO reports several stock options (rights to buy Class A Common Stock) with exercise prices including $10.09, $7.25, $8.55, $11.40, and $2.48, with expirations between 02/04/2032 and 02/03/2035, and vesting monthly under the schedules described.